WO1996016939A1 - Derives de perhydroisoindole comme antagonistes de la substance p - Google Patents
Derives de perhydroisoindole comme antagonistes de la substance p Download PDFInfo
- Publication number
- WO1996016939A1 WO1996016939A1 PCT/FR1995/001577 FR9501577W WO9616939A1 WO 1996016939 A1 WO1996016939 A1 WO 1996016939A1 FR 9501577 W FR9501577 W FR 9501577W WO 9616939 A1 WO9616939 A1 WO 9616939A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methoxy
- radical
- cyanomethyl
- mixture
- Prior art date
Links
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical class C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 title claims description 24
- 239000005557 antagonist Substances 0.000 title abstract description 4
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 132
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 52
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 19
- 125000005843 halogen group Chemical group 0.000 claims abstract description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims abstract description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims abstract description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims abstract description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 3
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims abstract description 3
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 3
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 3
- -1 hydroxy, amino Chemical group 0.000 claims description 116
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 239000002253 acid Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 10
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 claims description 9
- 102100037342 Substance-K receptor Human genes 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000002464 receptor antagonist Substances 0.000 claims description 9
- 229940044551 receptor antagonist Drugs 0.000 claims description 9
- 125000005335 azido alkyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- JKYNCKNIVHDOKU-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydroisoindol-1-one Chemical class C1CCCC2C(=O)NCC21 JKYNCKNIVHDOKU-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000001012 protector Effects 0.000 claims 1
- 101800003906 Substance P Proteins 0.000 abstract description 12
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract description 9
- 150000002367 halogens Chemical class 0.000 abstract description 4
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 abstract 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 237
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 207
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 168
- 230000002829 reductive effect Effects 0.000 description 93
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 78
- 239000000243 solution Substances 0.000 description 72
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 71
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 56
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 55
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- 238000002329 infrared spectrum Methods 0.000 description 52
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 50
- 239000000741 silica gel Substances 0.000 description 47
- 229910002027 silica gel Inorganic materials 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000011541 reaction mixture Substances 0.000 description 41
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 39
- 235000019341 magnesium sulphate Nutrition 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 38
- 239000000047 product Substances 0.000 description 38
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 36
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000002245 particle Substances 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 29
- 238000003756 stirring Methods 0.000 description 27
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- 238000011097 chromatography purification Methods 0.000 description 20
- 239000013078 crystal Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000010828 elution Methods 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- 230000009471 action Effects 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 13
- 229940022663 acetate Drugs 0.000 description 12
- 102400000096 Substance P Human genes 0.000 description 11
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 8
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 150000002518 isoindoles Chemical class 0.000 description 7
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- IVEWTCACRDEAOB-UHFFFAOYSA-N 2-(2-methoxyphenyl)acetic acid Chemical compound COC1=CC=CC=C1CC(O)=O IVEWTCACRDEAOB-UHFFFAOYSA-N 0.000 description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 229960000948 quinine Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 0 C[C@]1([C@@](CN(C2)C(C(*)*)=O)[C@]2C(*)(*)[C@@](*)C1)O Chemical compound C[C@]1([C@@](CN(C2)C(C(*)*)=O)[C@]2C(*)(*)[C@@](*)C1)O 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- FCPRDUXJWIUVPZ-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=CC=[C-]1 FCPRDUXJWIUVPZ-UHFFFAOYSA-M 0.000 description 3
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 150000002902 organometallic compounds Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- CCVYRRGZDBSHFU-UHFFFAOYSA-N (2-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1O CCVYRRGZDBSHFU-UHFFFAOYSA-N 0.000 description 2
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 2
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- UZULEJNWMHZSGY-UHFFFAOYSA-N 2-(2,3-dimethoxyphenyl)acetic acid Chemical compound COC1=CC=CC(CC(O)=O)=C1OC UZULEJNWMHZSGY-UHFFFAOYSA-N 0.000 description 2
- VFYKRBZHJFJOGQ-UHFFFAOYSA-N 2-(2-phenylmethoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1OCC1=CC=CC=C1 VFYKRBZHJFJOGQ-UHFFFAOYSA-N 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 150000003975 aryl alkyl amines Chemical class 0.000 description 2
- 229940007550 benzyl acetate Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyloxyacetoaldehyde Natural products CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- WUAXWQRULBZETB-UHFFFAOYSA-N homoveratric acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OC WUAXWQRULBZETB-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- KZMSVLOJRPGWDY-UHFFFAOYSA-N n-(butoxymethyl)-1-phenyl-n-(trimethylsilylmethyl)methanamine Chemical compound CCCCOCN(C[Si](C)(C)C)CC1=CC=CC=C1 KZMSVLOJRPGWDY-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- ZWAJLVLEBYIOTI-OLQVQODUSA-N (1s,6r)-7-oxabicyclo[4.1.0]heptane Chemical compound C1CCC[C@@H]2O[C@@H]21 ZWAJLVLEBYIOTI-OLQVQODUSA-N 0.000 description 1
- UUZURPUIMYJOIL-JNRWAQIZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound CSCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=CC=C1 UUZURPUIMYJOIL-JNRWAQIZSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical compound FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- IDDATTQMCPGIMG-UHFFFAOYSA-N 1h-triazol-1-ium;hydroxide Chemical compound O.C1=CNN=N1 IDDATTQMCPGIMG-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- AENVFIFDTPYLLD-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindol-1-ol Chemical compound C1CCCC2C(O)NCC21 AENVFIFDTPYLLD-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QFBYQIUBLBNTDO-UHFFFAOYSA-N 2-(2,6-dimethoxyphenyl)acetic acid Chemical compound COC1=CC=CC(OC)=C1CC(O)=O QFBYQIUBLBNTDO-UHFFFAOYSA-N 0.000 description 1
- UPEWDRCXLROYOF-UHFFFAOYSA-N 2-(2-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=CC=C1CC(Cl)=O UPEWDRCXLROYOF-UHFFFAOYSA-N 0.000 description 1
- YCAKYFIYUHHCKW-UHFFFAOYSA-N 2-(3,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(F)=C1 YCAKYFIYUHHCKW-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- BSPCSKHALVHRSR-UHFFFAOYSA-N 2-chlorobutane Chemical compound CCC(C)Cl BSPCSKHALVHRSR-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BPSNETAIJADFTO-UHFFFAOYSA-N 2-pyridinylacetic acid Chemical compound OC(=O)CC1=CC=CC=N1 BPSNETAIJADFTO-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- JKSIXVZIFHKAPJ-UHFFFAOYSA-N 2h-benzotriazole;hydrate Chemical compound O.C1=CC=C2NN=NC2=C1 JKSIXVZIFHKAPJ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical compound OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 description 1
- PBRUNEPVKSVOGQ-UHFFFAOYSA-N 5-chloro-n,n-dimethylpentan-1-amine Chemical compound CN(C)CCCCCCl PBRUNEPVKSVOGQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101100439211 Caenorhabditis elegans cex-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DIWVBIXQCNRCFE-UHFFFAOYSA-N DL-alpha-Methoxyphenylacetic acid Chemical compound COC(C(O)=O)C1=CC=CC=C1 DIWVBIXQCNRCFE-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical group ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- VEIYJWQZNGASMA-UHFFFAOYSA-N cyclohex-3-en-1-ylmethanol Chemical compound OCC1CCC=CC1 VEIYJWQZNGASMA-UHFFFAOYSA-N 0.000 description 1
- UYBXBOOBIVAIJM-UHFFFAOYSA-N cyclohex-3-en-1-ylmethyl acetate Chemical compound CC(=O)OCC1CCC=CC1 UYBXBOOBIVAIJM-UHFFFAOYSA-N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229950007593 homonicotinic acid Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- QAHLFXYLXBBCPS-IZEXYCQBSA-N methyl n-[(2s)-1-[[(5s)-5-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-6-hydroxyhexyl]amino]-1-oxo-3,3-diphenylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1C([C@H](NC(=O)OC)C(=O)NCCCC[C@@H](CO)N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C1=CC=CC=C1 QAHLFXYLXBBCPS-IZEXYCQBSA-N 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-OUBTZVSYSA-N potassium-40 Chemical compound [40K] ZLMJMSJWJFRBEC-OUBTZVSYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 108010052031 septide Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to new derivatives of perhydroisoin- dole of general formula:
- R- represents a phenyl radical optionally substituted by one or more halogen atoms or hydroxy, alkyl radicals which can be optionally substituted (by halogen atoms or amino, alkylammo or dialkoylammo radicals), alkyloxy or alkylthio which can be optionally substituted [ by hydroxy, amino, alkylammo or dialkylammo radicals optionally substituted (by phenyl, hydroxy or amino radicals), or dialkoylammo, the alkyl parts of which form, with the nitrogen atom to which they are attached, a 5 to 6-membered heterocycle which can contain another heteroatom chosen from oxygen, sulfur or nitrogen, optionally substituted by an alkyl, hydroxy or hydroxyalkyl radical), or substituted by amino, alkylam or dialkylammo radicals in which the alkyl parts can form with nitrogen atom to which they are attached, a heterocycle as defined above, or represents a cyclohexa
- the syrribole R2 represents a hydrogen or halogen atom or a hydroxy, alkyl, amino, aminoalkyl, alkyllaminoalkyl, dialkoylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy radical, alkyloxycarbonyl, dialkoylaminoalkyloxycarbonyl, benzyloxycarbonyl or acylamino,
- R3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical containing 1 or 2 carbon atoms, hydroxy or by a fluorine atom, or disubstituted by trifluoromethyl radicals, and
- R4 represents an alkyl radical containing 1 or 2 carbon atoms substituted by a halogen atom or by a cyano, az do or cyanamido radical
- R are identical or different and represent a hydrogen atom, an alkyl or phenyl radical.
- alkyl or acyl radicals mentioned above contain (unless special mention) 1 to 4 carbon atoms in a straight or branched chain.
- or R4 contains a halogen atom
- the latter can be chosen from chlorine, bromine, fluorine or iodine.
- R- represents a mono or polycyclic heterocyclyl radical, saturated or msaturated, by way of example it can be chosen from thienyl, furyl, pyridyl, dithimyl, dolyl, isoindolyl, benzothienyl, thiazolyl, isothiazolyl, oxazolyl, isidazolyl, pyrrolyl, triazolyl quinolyle, isoquinolyle, or naphty ⁇ d yle.
- R- represents phenyl substituted by a chain carrying a heterocycle
- the latter can be chosen from pyrrolidinyl, morpholino, piperidinyl, tetrahydropyridinyl, piperazinyl, thiomorpholmo.
- the perhydroisomdole derivatives of general formula (I) can be obtained by the action of the acid of general formula:
- R 4 is an azidoalkyl radical, optionally transforms this radical into a cyanoaminoalkyl radical.
- and / or R2 are preferably previously protected. Protection is effected by any compatible group, the establishment and elimination of which does not affect the rest of the molecule. In particular, we operate according to the methods described by TW Greene, Protective Groups in Organic Synthesis, A. Wiley - Interscience Publication (1981), or by Me O ie, Protective Groups Organic Chemistry, Plenum Press (1973).
- amino or alkylammo groups may be protected by methoxycarbonyl, ethoxycarbonyl, t.butoxycarbonyl, allyloxycarbonyl, vmyloxycarbonyl, trichlorethoxycarbonyl, trichloroacetyl, trifluoroacetyl, chloracetyl, benzylaryl, ethyl acetyl, benzyl acrylate radicals its substituted derivatives;
- the acid groups can be protected by ethyl, ethyl, t.butyl, allyl, benzyl, substituted benzyl or benzhydryl radicals.
- the operation is advantageously carried out using acid chloride, anhydride, a mixed anhydride or a reactive ester.
- the remainder of the ester is a succinimido radical, optionally substituted benzotr ⁇ azolyl-1, n ⁇ tro-4 phenyl, 2,4-dinitro-phenyl, pentachlorophenyl or phthalimido.
- the reaction is generally carried out at a temperature between
- an organic solvent such as a chlorinated solvent (dichloromethane, d chlorethane, chloroform for example), a hydrocarbon (toluene for example), an ether (tetrahydrofuran, dioxane for example), an ester (ethyl acetate for example), an amide (dimethylacetamide, dimethylfor amide for example), or a ketone (acetone for example) or in a mixture of these solvents, in the presence of an acceptor of acid such as an organic nitrogenous base such as, for example, pyridme, dimethylammopyridine, N-methylmorphol or an alkylamide (in particular triethylamine, dopropylethylamine) or such as an epoxide (propylene oxide for example).
- a chlorinated solvent dichloromethane, d chlorethane, chloroform for example
- a hydrocarbon toluene for example
- an ether tetrahydro
- a condensing agent such as a carbodumide, [for example dicyclohexyl-caibodumide or (d ⁇ méthylam ⁇ no-3 propyl) -1 ethyl-3 carbodumide], NN '-carbonyldumidazole or the 2-ethoxy-1-ethoxycarbonyl-1,2-hydro-olein or else in a hydroorganic medium, in the presence of an alkaline condensing agent such as sodium bicarbonate.
- a condensing agent such as a carbodumide, [for example dicyclohexyl-caibodumide or (d ⁇ méthylam ⁇ no-3 propyl) -1 ethyl-3 carbodumide], NN '-carbonyldumidazole or the 2-ethoxy-1-ethoxycarbonyl-1,2-hydro-olein or else in a hydroorganic medium, in the presence of an alkaline condensing agent such as sodium bicarbon
- the preparation of the amine is generally carried out by hydrogenation in the presence of palladium or palladium hydroxide on carbon in an organic solvent such as an alcohol (ethanol for example), an amide (dimethylformamide for example), an ether ( tetrahydrofuran for example), at a temperature between 20 and 80 ° C
- an organic solvent such as an alcohol (ethanol for example), an amide (dimethylformamide for example), an ether ( tetrahydrofuran for example), at a temperature between 20 and 80 ° C
- the reaction of cyanogen halide is carried out in a solvent such as an ether (tetrahydrofuran for example), an aromatic solvent (toluene for example), an alcohol (ethanol for example) at a temperature between 0 and 50 ° vs.
- a solvent such as an ether (tetrahydrofuran for example), an aromatic solvent (toluene for example), an alcohol (ethanol for example) at a temperature between 0 and 50 ° vs.
- R'4 represents a sulfonyloxy radical and n represents 1 or 2, by the action of an alkali cyanide, sodium azide or an alkali halide to obtain the derivative for which R4 is respectively cyanoalkyl, azidoalkyl or haloalkyl, then optionally transforms the product obtained for which R4 is azidoalkyl to a product for which R 4 is cyanoammoalkyl, or else optionally transforms the product obtained for which R4 is haloalkyl into a product of general formula (I) for which R4 is cyanoalkyl or azidoalkyl.
- the radical R ′ 4 can be p.toluenesulfonyloxy or methanesulfonyloxy.
- the reaction is carried out in particular by the action of potassium or sodium cyanide in an organic solvent such as in particular dimethyl sulfoxide , at a temperature between 20 and 80 ° C.
- the reaction is carried out by the action of sodium azide, in an organic solvent such as an amide ( dimethylformamide, dimethylacetamide for example) at a temperature between 10 and 50 ° C.
- an alkali halide such as for example lithium bromide, chloride of lithium, potassium fluoride, potassium iodide ...
- a solvent such as an alcohol (ethanol, methanol ...), a glycol (ethylene glycol, diethylene glycol ...), a ketone (acetone %), an ether (tetrahydrofuran, etc.) or a mixture of solvents, at a temperature between 20 ° C. and the reflux temperature of the reaction mixture.
- the reaction is carried out under conditions analogous to the preparation of the cyanoalkyl or azidoalkyl derivatives from the corresponding sulfonyloxyalkyl derivative.
- the iso dole derivative of general formula (III) can be obtained from the perhydroisoindole derivative of general formula:
- R5, R3, R'4 and n are defined as above and R5 is a protective radical, by analogy with the process for the preparation of perhydroisoindole derivatives of general formula (I) from a derivative of general formula (IV), then elimination of the protective radical R5.
- the protective radical 5 can be any amino protective group which is compatible with the reaction and the establishment and elimination of which does not alter the rest of the molecule.
- alkyloxycarbonyl benzyloxycarbonyl or benzyl groups
- allyl formyl, chloracetyl, trichloracetyl, trifluoroacetyl, vinyloxycarbonyl, allyloxycarbonyl, phenoxycarbonyl, chloro-1 ethoxycarbonyl or chlorocarbon groups.
- reaction is carried out under conditions identical to those described above for the preparation of the derivatives of general formula (I).
- subsequent elimination of the radical R5 is carried out according to known methods which do not affect the rest of the molecule; in particular according to the methods described by T.W. Greene, Protective Groups in Organic Synthesis, A. Wiley - Interscience Publication (1981), or by Me Omie, Protective Groups in Organic Chemistry, Plenum Press (1973).
- the perhydroisoindole derivative of general formula (V) can be obtained by the action of an organometallic compound of general formula:
- R3 is defined as above, and M represents lithium, a radical MgX or CeX2 for which X is an atom halogen, on the corresponding derivative of perhydroisoindolone of general formula:
- R, R ' 4 , R5 and n are defined as above.
- the reaction is carried out in an anhydrous medium, under the usual reaction conditions of the organometallic compounds with a ketone, which do not affect the rest of the molecule.
- the operation is carried out in an anhydrous ether (for example tetrahydrofuran or ethyl ether) optionally in the presence of anhydrous cerium chloride at a temperature between -78 and 30 ° C.
- the perhydroisoindole derivative of general formula (VII) can be obtained by the action of a sulphonic acid derivative of structure R'4-H on the hydroxylated derivative of general formula:
- the reaction is carried out in particular by the action of the acid chloride, in an organic solvent such as a halide (dichloromethane, dichlorethane, chloroform for example) in the presence of an organic nitrogenous base as mentioned above (triethylamme for example) .
- an organic solvent such as a halide (dichloromethane, dichlorethane, chloroform for example)
- an organic nitrogenous base as mentioned above (triethylamme for example) .
- perhydroisoindolone derivative of general formula (VIII) can be prepared as described below in the examples and by analogy with the methods described in patent application EP 429 366. It is understood that, depending on the nature of the substituents R desired, it will be necessary to start from the cyclohexenone suitably substituted.
- the perhydroisoindole derivative of general formula (IV) can be obtained by the action of a sulfonic acid derivative of structure R'4-H on the corresponding hydroxylated derivative of general formula:
- , R 2 , R3 and n are defined as above.
- reaction is carried out under conditions analogous to those described for obtaining the perhydroisoindolone of general formula (VII).
- the perhydroisoindole derivative of general formula (IX) can be obtained by the action of an acid of general formula (II) or its reactive derivative, on the perhydroisoindole derivative of general formula:
- R, R3 and n are defined as above.
- reaction is carried out by analogy with the preparation of the products according to the invention by condensation of an acid of general formula (II) on a perhydroisoindole derivative of general formula (III).
- the perhydroisoindole derivative of general formula (X) can be obtained by the action of an organometallic compound of general formula (VI) on the corresponding derivative of perhydroisoindolone of general formula (VIII) whose hydroxy radical in position 6 can be protected beforehand, operating by analogy with the preparation of the derivatives of general formula (V), then release of the protective radicals according to the usual methods that do not alter the rest of the molecule.
- reaction is carried out under the conditions described for obtaining the product of general formula (V) and as described in more detail in the examples. If necessary, the protection of the hydroxy radical in position 6 can be carried out according to known methods.
- the separation can be carried out by preparing an optically active salt, by the action of L (-t) or D (-) mandelic acid, or of dibenzoyltart ⁇ que or ditoluoyltartrique acid, then separation of the isomers by crystallization.
- the desired isomer is released from its salt in basic medium.
- Another alternative may also be, if necessary, to operate directly from an enantiomer of the starting cyclohexenone.
- the perhydroisoindole derivatives of general formula (III) are new products which also fall within the scope of the present invention.
- the isoindole derivatives of general formula (I) can be purified if necessary by physical methods such as crystallization or chromatography.
- the new derivatives of general formula (I) for which the symbols ⁇ and / or R 2 contain amino or alkylammo substituents, or the intermediates of general formulas (III), or (X) can be transformed into salts d addition with acids.
- addition salts with pharmaceutically acceptable acids mention may be made of the salts formed with mineral acids (hydrochlorides, hydrobromides, sulfates, nitrates, phosphates) or with organic acids (succinates, fumarates, tartrates, acetates, propionates, maleates, citrates, methanesulfonates, p.toluenesulfonates, isethionates, or with substitution derivatives of these compounds).
- the new isoindole derivatives of general formula (I) can also, where appropriate, when R represents a carboxy radical, be transformed into metal salts or into addition salts with a nitrogenous base, according to methods known per se.
- These salts can be obtained by the action of a metal base (for example alkaline or alkaline earth), ammonia or an amine, on a product according to the invention, in a suitable solvent such as an alcohol, a ether or water, or by exchange reaction with a salt of an organic acid.
- a metal base for example alkaline or alkaline earth
- ammonia or an amine on a product according to the invention
- a suitable solvent such as an alcohol, a ether or water
- the salt formed precipitates after optional concentration of the solution, it is separated by filtration, decantation or lyophilization.
- salts with alkali metals sodium, potassium, lithium
- oterrous alkali metals magnesium, calcium
- the ammonium salt the salts of nitrogenous bases (ethanolamme, diethanolamine, trimethylamine, triethylamine, methylamine, propylamine, diisopropylamine, NN-dimethylethanolamine, benzylamine, dicyclohexylamine, N-benzyl- ⁇ -phenethylamme, NN'-dibenzylethylene-diam e, diphenylenediamme, benzhyldrylamine, quinine, quinine, quinine leuc e, dibenzylamine).
- the new isomdole derivatives according to the present invention which antagonize the effects of substance P can find application in the fields of analgesia, inflammation, asthma, allergies, on the nervous system central, on the cardiovascular system, as an antispasmodic, as an antiemetic, or on the immune system, as well as in the field of stimulation of lachrymal secretions.
- the products according to the invention show an affinity for the substance P receptors at doses of between 0.3 and 1000 nM according to the techniques adapted from DG Payan et al., J. of immunology, 133 (6), 3260-5 (1984): Stereospecif c receptors for substance P on cultured human IM-9 lymphoblasts and from Me Pherson et al., J. Pharmacol. Meth., 14, 213 (1985): Analysis of radioligand binding expenments.
- Substance P is known to be involved in a number of pathological areas:
- Example 1 1 Example 5 3-30 Example 9 3-30
- isoindole derivatives according to the present invention do not exhibit any toxicity, they have been shown to be non-toxic in mice at a dose of 40 mg / kg by the subcutaneous route.
- the present invention also relates to the synergizing association consisting of at least one NK1 receptor antagonist of general formula (I) and at least one NK2 receptor antagonist.
- Neurok ine A The effects of neurok ine A are mediated mainly by NK2 receptors.
- Neurokmine A is involved in many pathologies such as pain transmission, arthritis, asthma, inflammatory phenomena, psychoses, blood pressure disorders, bladder disorders, cystitis ...
- NK2 receptor antagonists are known and described in particular and without limitation in patent applications EP 428 434, EP 474 561, EP 512 901, EP 515 240, FR 2 678 267, WO 92/19254 or WO 93/14084.
- NK2 receptor antagonists may in particular be derivatives of the class of arylalkylamines, the class of ⁇ -substituted polypeptides or of the class of piperidine derivatives ...
- NK2 receptor antagonists of the arylalkylamine class can be products of structure:
- NK2 receptor antagonist Y N- iCH 2 ) m — C— (CH 2 ) p — N — T- (CH 2 ) q ⁇ Z Ar and among these products a specific NK2 receptor antagonist is more particularly described by X. Emonds-Alt et al., Life Science, j> 0, PL 100 to PL 106 (1992).
- NK2 receptor antagonists of the class of ⁇ -substituted polypeptides can be products of structure:
- radicals can be residues of amino acids.
- NK2 receptor antagonists of the class of piperidine derivatives can for example be products of structure:
- the reaction mixture is cooled to 20 ° C, diluted with 300 cm 3 of water and then extracted with twice 50 cm 3 of ethyl acetate.
- the organic phase is then washed with 150 cm 3 of water, dried over magnesium sulfate and concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a column of silica gel (particle size 0.06-0.20 mm, diameter 4.4 cm, height 50 cm), eluting under a pressure of 0.2 bar of nitrogen with a mixture of cyclohexane and ethyl acetate (40/60 by volume) and by collecting 120 cm 3 fractions.
- (2-methoxy-phenyl) -4 [(2-methoxy-phenyl) -2 propionyl- (S)] -2 tosyloxymethyl-6 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6R, aR) can be prepared as follows: To a solution of 23.2 g of hydroxymethyl-6 (2-methoxy-phenyl) -4 [(2-methoxy-phenyl) -2 propionyl- (S)] -2 perhydro ⁇ somdolol-4- (mixture of the 2 diastereoisomers 3aR, 4R , 6S, 7aS, S and 3aS, 4S, 6R, 7aR, S) and with 14.9 cm 3 of triethylamine in 300 cm 3 of dichloromethane, 20.1 g of p.toluenesulfonyl chloride are added.
- reaction mixture is washed with 150 cm 3 of water and then dried over magnesium sulfate and concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a column of silica gel (particle size 0.06-0.20 mm, diameter 8.0 cm, height 45 cm), eluting under a pressure of 0.8 bar of nitrogen with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 500 cm 3 fractions. Fractions 14 to 17 are concentrated to dryness under reduced pressure.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3560 + 3510, 3425, 3110 + 3070, 2930, 2890, 2860, 2840, 1635, 1600 + 1580 + 1495, 1460 + 1430, 1360, 1240, 1190 + 1180, 1100, 1060, 1035, 965, 815, 760, 670, 580 + 560.
- Infrared spectrum (characteristic bands in cm -1 ): 3480, 3425, 3110 + 3070, 2930, 2880, 2840, 1625, 1600 + 1585 + 1495 + 1490, 1460, 1410, 1240, 1110, 1080, 1060, 1030 , 970, 750.
- Hydroxymethyl-6 (2-methoxy-phenyl) -4 perhydro ⁇ somdolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3420, 3075, 2920, 2880, 1595, 1575, 1485, 1460, 1235, 1055, 1030, 755.
- Benzyl-2-hydroxymethyl-6 (2-methoxy-phenyl) -4 perhydroisoindolol- 4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3560, 3420, 3060, 3025, 3005, 2910, 2850, 2800, 1590, 1575, 1495, 1480, 1230, 1055, 1030, 755, 735, 700.
- Acetoxymethyl-6 benzyl-2 perhydro ⁇ soindolone-4- (3aRS, 6SR, 7aSR) can be prepared as follows:
- CCI4 Infrared spectrum
- characteristic bands cm -1 : 3105, 3090, 3065, 3030, 2920, 2795, 1745, 1712, 1605, 1585, 1495, 1455, 1425, 1365, 1240, 1035, 700.
- Acetoxymethyl-5 cyclohexene-2 one-1 can be prepared according to the method described by DIPAKRANJAN MAL and Coll, J. Chem. Soc. Perkin Trans. 1, 309, (1994).
- (2-methoxyphenyl) -2-propionic acid (S) can be prepared, by analogy with the methods described by DA Evans et al., Tetrahedron, 4_4, 5525, (1988), according to the following procedure :
- 4-methylphenyl-5 [(2-methoxyphenyl) -2- (S) -propionyl] -3 oxazolinidone-2- (4S, 5S) can be obtained in the following way: To a solution cooled to -50 ° C of 10 g of 4-methylphenyl-5 [(2-methoxyphenyl) -acetyl] -3 oxazol ⁇ d ⁇ none-2- (4S, 5S) in 150 cm of tetrahydrofuran is added 19.1 g of sodium hexamethyl-1, 1, 1, 3, 3.3, disilazanate, the mixture is stirred for 45 minutes at this temperature, then 7.72 cm of methyl iodide are added. The reaction mixture is then stirred for 15 hours at room temperature, then diluted with
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3430, 3110 + 3070 + 3025, 2950, 2880 + 2890, 2855, 2840, 2825, 2250, 1625, 1600 + 1585 + 1495 + 1485, 1450, 1250, 1105, 1060, 1090, 1025, 960, 755, 587.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6RS, 7aSR) can be prepared as follows:
- the cyanomethyl-6 (2-methoxy-phenyl) -4 perhydroiso-mdolol-4- (3aRS, 4RS, 6RS, 7aSR) hydrochloride obtained is taken up in 400 cm 3 of dichloromethane and after addition of 160 cm 3 of 4N sodium hydroxide, organic phase is washed with 300 cm 3 of water, dried over magnesium sulfate, then concentrated to dryness under reduced pressure (2.7 kPa).
- 103 g of cyanomethyl-6 (2-methoxy-phenyl) -4 perhydroiso- ⁇ ndolol-4- ((3aRS, 4RS, 6RS, 7aSR) are obtained in the form of a yellowish white solid.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3345, 2980, 2950, 2950, 2785 + 2760 + 2470 + 2410, 2240, 1600, 1575, 1485, 1460, 1435, 1240, 1100, 1060, 1025, 950, 765.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 perhydro- ⁇ somdolol-4- (3aRS, 4RS, 6RS, 7aSR) trifluoroacetate can be prepared by treating a solution of 8.5 g of cyanomethyl-6 (2-methoxyphenyl) ) -4 tert-butyl-oxycarbonyl-2 perhydro ⁇ so ⁇ ndolol-4- (3aRS, RS, 6RS, 7aSR) in 170 cm 3 of dichloromethane per 12.6 cm 3 of trifluoroacetic acid, at 20 C C for 4 hours.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 tert ⁇ obutyloxycarbonyl-2 perhydro ⁇ somdolol-4- (3aRS, 4RS, 6RS, 7aSR) can be prepared as follows:
- (2-methoxy-phenyl) -4 tert ⁇ obutyloxycarbonyl-2 tosyloxymethyl-6 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows: To a suspension cooled to + 5 ° C.
- tertiary butyloxycarbonyl-2 tosyloxymethyl-6 perhydro ⁇ so ⁇ ndolone-4- (3aRS, 6SR, 7aSR) can be prepared as follows:
- Infrared spectrum (CC1 4 ), characteristic bands (cm -1 ): 2980, 2930, 2900, 1720, 1700, 1600 + 1495, 1480, 1455, 1405, 1395, 1365, 1190 + 1180, 1165, 1110, 1100 +1020, 980, 880, 825, 670 + 570 + 555.
- Hydroxymethyl-6 tert ⁇ obutyloxycarbonyl-2 perhydro ⁇ so ⁇ ndolone-4- (3aRS, 6SR, 7aSR) can be prepared by hydrogenation at atmospheric pressure for two hours from a suspension brought to 50 ° C of 513 g of 6-acetoxymethyl-benzyl-2 perhydro ⁇ so ⁇ ndolone-4- (3aRS, 6SR, 7aSR) and 103 g of 20% palladium hydroxide on black in 5.13 liters of ethanol and 157 cm 3 of 35% hydrochloric acid. The reaction mixture is then filtered, concentrated to dryness under reduced pressure (2.7 kPa).
- the organic phase is washed cold with 2.5 liters of a 3% aqueous citric acid solution, with two liters of water, two liters of brine, then dried over magnesium sulfate and concentrated to dryness under reduced pressure.
- 22 liters of methanol, 6.6 liters of water and 660 g of sodium carbonate are added to the red oil obtained.
- the mixture is stirred at 60 ° C for 2 hours then 20 hours at 20 ° C.
- concentration at reduced volume the mixture is extracted with 3 liters and 1.5 liters of ethyl acetate, the extracts are washed with 4 times a liter of brine then dried over magnesium sulphate and concentrated to dryness under pressure scaled down.
- 3aRS, 6SR, 7aSR 6-hydroxymethyl tert-butyloxycarbonyl-2 perhydro ⁇ so ⁇ ndolone-4-
- CCI4 Infrared spectrum
- characteristic bands cm -1 : 3635, 3440, 2980, 2920 + 2930, 2880, 1720, 1695 + 1680, 1480, 1455 + 1445, 1405, 1395 + 1365, 1240, 1165, 1110, 1060 + 1050, 875.
- Cyanomethyl-6 [(2-methoxy-6, phenyDacetyl] -2 (2-methoxy-phenyl) - 4 perhydro ⁇ so ⁇ ndolol-4 (3aRS, 4RS, 6RS, 7aSR) can be prepared in operating according to the method described in Example 2, from 0.5 g of cyanomethyl-6 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aRS, 4RS, 6RS, 7aSR), 50 cm 3 of dichloromethane, 0.05 g of hydroxybenzotriazole hydrate, 0.34 g of (2,6-dimethoxy-6 phenyl) acetic acid, and 0.37 g of (3-dimethylamino propyl) -1 ethyl-3 carbodumide.
- (2,6-dimethoxyphenyl) acetic acid can be prepared according to the method of F. E. KING and M. F. GRUNDON., Chem. Soc. Transactions, 3547 - 3552 (1950).
- reaction mixture is washed with twice 50 cm 3 of water, dried over magnesium sulfate, and concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a column of silica gel (particle size 0.04-0.06 mm, diameter 4.8 cm, height 44 cm), eluting under a pressure of 0.4 bar of nitrogen, with a mixture dusopropyl ether and ethyl acetate (75/25, then 60/40 then 50/50 by volume and ending with ethyl acetate), and collecting fractions of 125 cm 3 .
- Fractions 65 to 73 are concentrated to dryness under reduced pressure (2.7 kPa).
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3410, 3110 + 3065 + 3030, 2930, 2880, 2835, 2245, 1630, 1600 + 1590 + 1495, 1450 + 1435, 1240, 1120 + 1110, 1060 + 1050, 1025, 960, 755, 700.
- Cyanomethyl-6 [(2-hydroxyphenyl) -2 propionyl- (S)] -2 (methoxy-2 phenyl) -4 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6S, 7aR) can be prepared by hydrogenation under atmospheric pressure for 2 hours of a suspension of 0.59 g of cyanomethyl-6 [(2-benzyloxy-phenyl) -2 propionyl- (S)] -2 (2-methoxy-phenyl) -4 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6S, 7aR) and 0.06 g of 20% palladium hydroxide on carbon black in 30 cm 3 of ethanol.
- N- [(2-benzyloxyphenyl) -2- (S) propionyl] camphor-2, 10-sultame- (1R, 2S) can be prepared as follows:
- reaction mixture is extracted with 80 cm 3 of ethyl acetate, the organic phase is washed twice with 25 cm of a saturated aqueous ammonium chloride solution, dried over magnesium sulfate and concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a Merck silica gel column (particle size 0.04-0.06 mm, diameter 4 cm, height 39 cm), eluting under a pressure of 0.3 bar of nitrogen with dichloromethane and collecting 25 cm fractions. Fractions 21 to 53 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue is crystallized from dusopropyl ether.
- N- [(2-benzyloxy phenyl) -acetyl] camphor-2, 10-sultame- (1R, 2S) can be prepared in the following way:
- Cyanomethyl-6 (2-methoxyphenyl) -4 perhydroiso-mdolol-4- (3aS, 4S, 6S, 7aR) hydrochloride can be prepared as described in Example 2, starting from 28.7 g of cyanomethyl- 6 (2-methoxy-phenyl) -4 tert ⁇ obutyloxycarbonyl-2 perhydro ⁇ somdolol-4- (3aS, 4S, 6S, 7aR), 230 cm 3 of dioxane, 70 cm 3 of 6N hydrochloric dioxane.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3330, 2975, 2950, 2915 + 2855, 2840, 2770 + 2745 + 2460 + 2380, 2245, 1595, 1570, 1480, 1455 + 1465, 1435, 1420, 1240, 1100, 1050, 1020, 955, 775 + 760.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 tert ⁇ obutyloxycarbonyl-2 perhydro ⁇ somdolol-4- (3aS, 4S, 6S, 7aR) can be prepared as described in Example 2, starting from 42 g of (2-methoxyphenyl ) -4 tert-butyloxycarbonyl-2 tosyloxymethyl-6 perhydro ⁇ somdolol-4- (3aS, 4S, 6R, 7aR), 200 cm 3 of dimethylsulfoxide, and 7.7 g of potassium cyanide.
- (2-methoxy-phenyl) -4 tert-butyloxycarbonyl-2 tosyloxymethyl-6 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6R, 7aR) can be prepared by operating as described in Example 2, starting from 2-methoxyphenylmagnesium bromide (prepared from 30 cm 3 of bromo-2 anisole and 5.8 g of magnesium), 200 cm 3 of tetrahydrofuran, 55.6 g of tert-butyloxycarbonyl-2 tosyloxymethyl-6 perhydroisoindolone-4- (3aS, 6R, 7aR ), and 300 cm 3 of tetrahydrofuran.
- 2-methoxyphenylmagnesium bromide prepared from 30 cm 3 of bromo-2 anisole and 5.8 g of magnesium
- 200 cm 3 of tetrahydrofuran 55.6 g
- the tertiary butyloxycarbonyl-2 tosyloxymethyl-6 perhydro ⁇ somdolone-4- (3aS, 6R, 7aR) can be prepared by operating as described in example 2, starting from 35 g of hydroxymethyl-6 tert ⁇ obutyloxycarbonyl-2 perhydro ⁇ so ⁇ ndolone-4- (3aS , 6R, 7aR), of 350 cm 3 of dichloromethane, 36.4 cm 3 of triethylam e, and 49.5 g of paratoluene-sulfonyl chloride.
- Hydroxymethyl-6 tert ⁇ obutyloxycarbonyl-2 perhydro ⁇ so ⁇ ndolone-4- (3aS, 6R, 7aR) can be prepared by hydrogenating at atmospheric pressure for 2 hours, a mixture of 34 g of acetoxymethyl-6 benzyl-2 perhydro ⁇ somdolone-4- (3aS , 6R, 7aR), 6 g of palladium hydroxide on black, 140 cm 3 of ethanol, 12 cm 3 of 35% hydrochloric acid. The reaction mixture is then filtered, concentrated to dryness under reduced pressure (2.7 kPa).
- Acetoxymethyl-6 benzyl-2 perhydro ⁇ somdolone-4- (3aS, 6R, 7aR) can be prepared by operating according to the method described in Example 1, starting from 80 g of 5-acetoxymethyl-2-cyclohexene one-1 - (R), 168 g of N-butoxymethyl N-trimethylsilylmethyl benzylamine, 800 cm 3 of dry dichloromethane, and 5 drops of trifluoroacetic acid. 83 g of 6-acetoxymethyl-2-benzyl-perhydro ⁇ so ⁇ ndolone-4- (3aS, 6R, 7aR) are obtained, after chromatographic purification, in the form of an oil used as it is in the next step.
- 5-acetoxymetyl cyclohexè ⁇ e-2 one-1- (R) can be prepared as follows:
- Example 4 By operating as described in Example 4, starting from 1.61 g of cyanomethyl-6 hydrochloride (2-methoxyphenyl) -4 perhydroiso- mdolol-4- (3aS, 4S, 6S, 7aR), 50 cm 3 of dichloromethane, 0.70 cm 3 of triethylamme, 1.21 g of (2-benzyloxy-phenyl) acetic acid, 0.02 g of hydroxybenzotriazole hydrate, and 1.05 g of (3-methylpropyl propyl) - 1 ethyl-3 carbodumide.
- Cyanomethyl-6 [(2-hydroxyphenyl) acetyl] -2 (2-methoxy phenyl) -4 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6S, 7aR) is obtained by operating as described in Example 4, starting from 1.3 g cyanomethyl-6
- Cyanomethyl-6 [(d ⁇ chloro-3, 4 phenyl) acetyl] -2 (methoxy-2 phenyl) -4 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 5 , from 0.65 g of cyanomethyl-6 hydrochloride (2-methoxy-phenyl) -4 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6S, 7aR), 0.28 cm 3 of triethylamme, 0.41 g of 3,4-phenylacetic acid, 5 mg of hydroxybenzotriazole hydrate, and 0.42 g of (3-methylamino-propyl) -1 ethyl-3 carbodumide.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3410, 3070, 2930, 2885 + 2850, 2835, 2245, 1630, 1600 + 1580 + 1560 + 1485 + 1470, 1460 + 1435, 1235, 1130, 1105, 1030, 960, 875 + 810, 755.
- Cyanomethyl-6 [( ⁇ ndolyl-3) acetyl] -2 (2-methoxyphenyl) -4 perhydro- ⁇ so ⁇ ndolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 5, from 0.65 g of cyanomethyl-6 (2-methoxy-phenyl) -4 hydrochloride perhydro ⁇ somdolol-4- (3aS, 4S, 6S, 7aR), 0.35 g of 3-indolyl acetic acid, 0.05 g of hydroxybenzotriazole hydrate, 0.28 cm 3 of triethylamme, and 0.42 g of (d ⁇ méthylam ⁇ no-3 propyl) -1 ethyl-3 carbodumide.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3535, 3430, 3230, 3105 + 3080 + 3055 + 3025, 2960, 2925 + 2905, 2880, 2855, 2840, 2250, 1630, 1583 + 1490, 1460, 1432, 1340, 1285, 1240 + 1235, 1115 + 1105, 1025, 955, 750 + 745.
- the crude product is chromatographed on a column of silica gel (particle size 0.06-0.20 mm, diameter 4 cm, height 30 cm) under a pressure of 0.5 bar of nitrogen in a mixture of acetate ethyl and cyclohexane (50/50 by volume) and collecting 120 cm 3 fractions. Fractions 4 to 16 are concentrated to dryness under reduced pressure (2.7 kPa). 4.55 g of [tertiobutyloxycarbonylamino-2 phenyl-2 acetyl- (S)] -2 cyanomethyl-6 (2-methoxy-phenyl) -4 perhydroisomdolol-4- (3aS, 4S, 6S, 7aR) are obtained. the shape of a whitish meringue.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3410, 3380 + 3300, 3075 + 3055 + 3025 + 3005, 2965 + 2950 + 2935, 2910 + 2885 + 2860, 2835, 2245, 1640, 1600 + 1580 + 1485, 1545, 1460 + 1445, 1245, 1105, 1030, 970, 755, 700.
- Example 14 By operating according to the procedure of Example 14 below, starting from 0.63 g of 6-cyanomethyl-4-phenyl-hydrochloride-4-isoindolol-4- (3aRS, 4RS, 6RS, 7aSR) hydrochloride and 0, 39 g of 2-methoxyphenylacetic acid, 0.56 g of cyanomethyl-6 phenyl-4 is obtained (2-methoxyphenylacetyl) -2 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6RS, 7aSR) in the form of a white meringue.
- Infrared spectrum (characteristic bands in cm -1 ): 3580, 3400, 2980 + 2950, 2890, 2855, 2840, 2250, 1635, 1605 + 1580 + 1495, 1450, 1250, 1115, 1050, 1035, 970.
- 6-cyanomethyl-4-phenyl hydrochloride perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6RS, 7aSR) can be prepared as follows:
- Cyanomethyl-6 phenyl-4 tert-butyloxycarbonyl-2 perhydroisoindolol- 4- (3aRS, 4RS, 6RS, 7aSR) can be prepared as follows:
- P-Toluenesulfonyloxymethyl-6 phenyl-4 tert-butyloxycarbonyl-2 perhydroisoindolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- the organic phase is washed with 20 cm 3 of a saturated sodium chloride solution, dried over magnesium sulfate, then concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a column of silica gel (particle size 0.04-0.06 mm, diameter 3 cm, height 25 cm), eluting under a pressure of 0.5 bar of nitrogen with a mixture of cyclohexane and d ethyl acetate (80/20 by volume) and collecting 25 cm 3 fractions. Fractions 16 to 40 are combined and then concentrated to dryness under reduced pressure (2.7 kPa).
- P-Toluenesulfonyloxymethyl-6 (2-fluoro-phenyl) -4 (2-methoxyphenylacetyl) -2 perhydro ⁇ somdolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- P-Toluenesulfonyloxymethyl-6 (2-fluoro-phenyl) -4 [(2-methoxy-phenyl) -2 propionyl- (S)] -2 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6R, 7aR) can be obtained in this way next : To a solution of 1.17 g of hydroxymethyl-6 (2-fluoro-phenyl) -4 [(2-methoxy phenyl) -2 propionyl- (S)] -2 perhydro ⁇ so ⁇ ndolol-4- (3aS, 4S, 6R, 7aR ) in 30 cm 3 of dichloromethane is added, at room temperature, 4.2 g of p-toluenesulfonyl chloride, then 3.1 cm 3 of triethylamme.
- reaction mixture is stirred at this temperature for 18 hours, then washed with 2 times 25 cm 3 of water, then with 25 cm 3 of a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a column of silica gel (particle size 0.04-0.06 mm, diameter 2.8 cm, height 25 cm), eluting under a pressure of 0.8 bar of nitrogen with a mixture of cyclohexane and ethyl acetate (60/40 by volume) and collecting 25 cm 3 fractions. Fractions 22 to 35 are combined and then concentrated to dryness under reduced pressure (2.7 kPa).
- reaction mixture is stirred for 18 hours at room temperature, then washed with 50 cm 3 of water, then with 50 cm 3 of a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated to dryness under reduced pressure ( 2.7 kPa).
- the residue is chromatographed on a silica gel column (particle size 0.04-0.06 mm, diameter 4.5 cm, height 29 cm), eluting under a pressure of 0.5 bar of nitrogen with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 75 cm 3 fractions. Fractions 81 to 99 are combined and then concentrated to dryness under reduced pressure (2.7 kPa).
- Hydroxymethyl-6 (2-fluoro-phenyl) -4 hydrochloride-indolol-4- (3aRS, 4RS, 6SR, 7aSR) hydrochloride can be obtained as follows:
- Hydroxymethyl-6 (fluoro-2 phenyl) -4 tert-butyloxycarbonyl-2 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- reaction mixture is then stirred for 48 hours at room temperature, then it is treated with 50 cm 3 of a saturated aqueous ammonium chloride solution, extraction is carried out with 200 cm 3 of ethyl acetate, the organic phase is washed with 100 cm 3 of a saturated solution of sodium chloride, dried over magnesium sulfate and concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on silica gel column (particle size 0.04-0.06 mm, diameter 6 cm, height 35 cm), eluting under a pressure of 0.5 bar of nitrogen with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 75 cm 3 fractions.
- Example 13 By operating according to the procedure of Example 13, starting from 1.67 g of p-toluenesulfonyloxymethyl-6 (2-fluoro-phenyl) -4 (2-benzyloxy-phenylacetyl) -2 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6RS, 7aSR) and 0.104 g of potassium cyanide, 0.35 g of cyanomethyl-6 (2-fluoro-phenyl) -4 (2-benzyloxyphenylacetyl) -2 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6SR, is obtained) 7aSR) in the form of a pink meringue.
- Infrared spectrum characteristic bands in cm -1 : 3430, 3080 + 3040, 2925, 2890, 2855, 2790 + 2745 + 2640, 2250, 1625, 1600 + 1490 + 1485, 1460, 1255, 1210, 1100, 1040 , 970, 760.
- P-Toluenesulfonyloxymethyl-6 (2-fluoro-phenyl) -4 (2-benzyloxyphenylacetyl) -2 perhydro ⁇ somdolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- Example 13 By operating according to the procedure of Example 13, starting from 0.72 g of hydroxymethyl-6 (2-fluoro-phenyl) -4 (2-benzyloxyphenylacetyl) -2 perhydro ⁇ so ⁇ ndolol-4- (3aRS, 4RS, 6SP , 7aSR), 0.55 g of p-toluenesulfonyl chloride and 0.4 cm 3 of triethylamme, after purification on a column of silica gel (particle size 0.04-0.06 mm, diameter 2), 4 cm, height 20 cm), eluting under a pressure of 0.5 bar of nitrogen with a mixture of cyclohexane and ethyl acetate (50/50 by volume), 0.51 g of p-toluenesulfonyloxymethyl- 6 (2-fluoro phenyl) -4 (2-benzyloxyphenylacetyl) -2 perhydro ⁇ so ⁇ ndolol-4- (3
- reaction mixture is stirred at room temperature for 18 hours, then the organic phase is washed with 10 cm 3 of water, then with 10 cm 3 of a saturated aqueous sodium chloride solution, dried over magnesium sulfate and concentrated to dry under reduced pressure (2.7 kPa).
- the residue is chromatographed on a silica gel column (particle size 0.04-0.06 mm, diameter 3.2 cm, height 20 cm), eluting under a pressure of 0.5 bar of nitrogen with acetate ethyl and collecting 25 cm 3 fractions. Fractions 18 to 50 are combined and then concentrated to dryness under reduced pressure (2.7 kPa).
- P-Toluenesulfonyloxymethyl-6 (2-fluoro-phenyl) -4 [(pyrrolidinyl- 1) -2 phenylacetyl] -2 perhydroisoindolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- Example 13 By operating according to the procedure of Example 13, starting from 0.2 g of 6-hydroxymethyl (2-fluoro-phenyl) -4 [(pyrrolidinyl-1) -2 phenylacetyl] -2 perhydroisoindolol-4- (3aRS , 4RS, 6SR, 7aSR), 0.168 g of p-toluenesulfonyl chloride and 0.124 cm 3 of triethylamine, 0.07 g of p-toluenesulfonyloxymethyl-6 (2-fluoro-phenyl) -4 [(pyrrolidinyl-1) is obtained ) -2 phenylacetyl) -2 perhydroisoindolol-4- (3aRS, 4RS, 6SR, 7aSR) in the form of a white meringue.
- Example 14 By operating according to the procedure of Example 14, from 0.73 g of hydroxy ⁇ ethyl-6 hydrochloride (2-fluoro-phenyl) -4 perhydroisoindolol-4- (3aRS, 4RS, 6SR, 7aSR) and from 0 , 68 g of (pyrrolidinyl-1) -2 phenylacetic acid, 0.2 g of hydroxymethyl-6 (2-fluoro-phenyl) -4 [((pyrrolidinyl-1) -2 phenylacetyl] -2 perhydro-isoindolol- is obtained 4- (3aRS, 4RS, 6SR, 7aSR) in the form of a white meringue.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3400, 3070, 2925, 2880, 2835, 2095, 1625, 1600 + 1580 + 1495 + 1480, 1460, 1435, 1285, 1245 + 1235, 1105, 1050, 1030, 960, 755.
- (2-methoxy-phenyl) -4 [(2-methoxy-phenyl) acetyl] -2 tosylmethyl-6 perhydroisoindolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3430, 3075, 3000-2875, 2835, 1620, 1605, 1495, 1485, 1460, 1435, 1245, 1055, 1030, 750.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3410, 3200, 3070, 2925, 2880, 2840, 2215, 1620, 1600 + 1490 + 1 80, 1460, 1435, 1285, 1245 + 1235, 1105 , 1050, 1030, 960, 755.
- Aminomethyl-6 (2-methoxy phenyl) -4 [(2-methoxy phenyl) acetyl] -2 perhydroisoindolol-4- (3aRS, 4RS, 6SR, 7aSR) can be prepared as follows:
- the combined organic extracts are then washed with 20 cm 3 of brine, dried over magnesium sulfate and then concentrated to dryness under reduced pressure (2.7 kPa).
- the residue is chromatographed on a column of silica gel (particle size 0.04-0.063 mm, diameter 1.5 cm, height 35 cm), under a pressure of 0.1 bar of nitrogen, eluting with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 25 cm 3 fractions.
- Fractions 15 to 22 are concentrated to dryness and then the residue is concrete in dusopropyl ether.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3560 + 3430, 3110 + 3070, 2970 + 2935, 2885, 2835, 1625, 1600 + 1585 + 1 90, 1460 + 1435, 1250, 1105, 1060 , 1030, 1020 + 1000, 960, 795, 755.
- Cyanomethyl-6 (2-methoxy phenyl) -4 [2-phenyl propionyl- (S)] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared as follows:
- reaction medium After 20 hours of stirring at 20 ° C, the reaction medium is washed twice with 30 cm 3 of water, dried over magnesium sulfate, then concentrated to dryness under reduced pressure (2.7 kPa).
- the residue obtained is chromatographed on a silica gel column (particle size 0.04 - 0.063 mm, height 32 cm, diameter 2.8 cm), eluting under a pressure of 0.6 bar of nitrogen, with a mixture of cyclohexane and ethyl (50/50 by volume), and collecting 25 cm 3 fractions. Fractions 19 to 35 are concentrated to dryness under reduced pressure (2.7 kPa).
- Cyanomethyl-6 [(2-fluoro phenyl) acetyl] -2 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21 , from 0.32 g of cyanomethyl-6 (2-methoxy-phenyl) -4 hydrochloride-isoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0.155 g of acid ( 4-fluoro phenyl) acetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(2-tolyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in the example 21, from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-isoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0.147 g of acid orthotolylacetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(3-thienyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 perhydro-isoindolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.140 g of thienyl acid 3 acetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g hydroxybenzotriazole hydrate, and 0.210 g (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 [2-methoxy-2-phenyl acetyl- (S)] -2 (2-methoxy-phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, starting with 0.32 g of cyanomethyl-6 (2-methoxy-phenyl) -4 hydrochloride-isoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0.170 g 2-methoxy-2-phenylacetic acid, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino propyl) -1 ethyl-3 hydrochloride carbodumide. After chromatographic purification is obtained (silica gel 0.06
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600 3250 3073; 3030, 2940; 2886; 2853, 2838, 2244, 1635, 1600; 1582; 1486; 1452; 1438, 1452, 1236, 1105, 1029, 759, 700.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(2-thienyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, from 0.32 g of cyanomethyl-6 (2-methoxy-phenyl) -4 hydrochloride-isoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0.14 g of acid 2-thienyl acetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 [(2,3-dimethoxy phenyl) acetyl] -2 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in example 21, from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride perhydro-isoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0.196 g of (2,3-dimethoxy phenyl) acetic acid, 0.21 cm 3 of diisopropyl ⁇ ethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- the (2,3-dimethoxyphenyl) acetic acid can be prepared according to the method described by W. WENNER., J. Org. Chem, 548 (1950).
- Example 28 [(2-Chloro-phenyl) acetyl] -2 cyanomethyl-6 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-isoindolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.17 g 2-phenyl acetic acid, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 (methoxy-2 phenyl) -4 phenylacetyl-2 perhydro-isoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, starting from 0.32 g of cyanomethyl-6 hydrochloride (2-methoxy-phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0.140 g of phenylacetic acid, 0.21 cm 3 diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 [(3,4-dimethoxy phenyl) acetyl] -2 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.200 g (3,4-dimethoxyphenyl) acetic acid, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino propyl) -1 ethyl-3 hydrochloride carbodumide.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600 3250, 3075, 2937; 2886, 2836, 2243, 1622, 1592; 1516; 1485; 1456; 1436, 1556, 1236, 1027, 788, 760.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(2-trifluoromethyl phenyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21 , from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.200 g of acid ( trifluoromethyl-2 phenyl) acetic, 0.21 cm 3 of diisopropylethyl- amino, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(4-methoxy-phenyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21 , from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.166 g of acid
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600 3250, 3070, 2937; 2884, 2836, 2243, 1620, 1582; 1513; 1485; 1454; 1438, 1454, 1245, 1030, 812, 757.
- Cyanomethyl-6 (2-methoxy phenyl) -4 [(3-methoxy phenyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21 , from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.166 g of acid ( 3-methoxyphenyl) acetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino-propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 [(3-fluoro phenyl) acetyl] -2 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21 , from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.155 g of acid ( 4-fluoro phenyl) acetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino propyl) -1-ethyl-3-carbodumide hydrochloride.
- Cyanomethyl-6 [(4-fluoro phenyl) acetyl] -2 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21 , from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.155 g of acid ( 4-fluoro phenyl) acetic, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.210 g of (3-dimethylamino propyl) -1-ethyl-3-carbodumide hydrochloride.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600 3250, 3070; 3050, 2931; 2885, 2840, 2244, 1624, 1582; 1510; 1485; 1454; 1437, 1554, 1234, 1027, 816, 758.
- Cyanomethyl-6 [(3,4-difluoro phenyDacetyl] -2 (2-methoxyphenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, from 0.32 g of cyanomethyl-6 (2-methoxyphenyl) -4 hydrochloride-indolol-4- (3aS, 4S, 6S, 7aR) hydrochloride, 25 cm 3 of dichloromethane, 0.17 g 3,4-difluoro-phenylacetic acid, 0.21 cm 3 of diisopropylethylamine, 0.01 g of hydroxybenzotriazole hydrate, and 0.21 g of (3-dimethylamino-propyl) hydrochloride-3 ethyl-carbodumide
- chromatographic purification sica gel 0.06 - 0.200 mm, elution with a mixture
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600; 3250, 3072, 2940; 2880; 2850, 2838, 2243, 1625, 1581; 1515; 1485; 1453; 1437, 1453, 1235, 1028, 757.
- Cyanomethyl-6 [2-hydroxy-phenyl-2 acetyl- (S)] -2 (methoxy-2 phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR), can be prepared by operating as it is described in Example 1, from 1.4 g of cyanomethyl-6 hydrochloride (2-methoxy phenyl) -4 perhydroiso- indolol- (3aS, 4S, 6S, 7aR), 40 cm 3 of dichloromethane, 0 , 66 g of S- (+) -mandelic acid, 0.02 g of hydroxybenzotriazole hydrate, 0.88 cm 3 of diisopropylethylamine, and 0.93 g of (3-dimethylamino propyl) -1 ethyl hydrochloride -3 carbodumide.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(2-methoxy-phenyl) -2 propionyl- (R)] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as it is described in Example 5, from 0.57 g of cyanomethyl-6 (2-methoxy-phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR), 30 cm 3 of dichloromethane, 0.20 cm 3 of diisopropylamine, 0.36 g of (methoxy-2 phenyl) -2- (R) - propionic acid, prepared according to T.
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3410, 3060, 2930, 2830, 2245, 1620, 1600 + 1580 + 1490, 1240, 1030, 755.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(2-pyridyl) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 9, from 0.57 g of cyanomethyl-6 (2-methoxy phenyl) -4 perhydroisoindolol-4-
- Cyanomethyl-6 (2-methoxy-phenyl) -4 [(pyridyl-3) acetyl] -2 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 9, from 0.57 g of cyanomethyl-6 (2-methoxy phenyl) -4 perhydroisoindolol-4-
- Infrared spectrum (KBr), characteristic bands (cm -1 ): 3420, 3060 + 3030, 2945, 2850, 2840, 2245, 1640, 1600 + 1580 + 1485, 1240, 1030, 790, 760, 705.
- Cyanomethyl-6 (2-methoxy-phenyl) -4 ⁇ [((pyrrolidinyl-1) -3 propoxy] - 2 phenyl ⁇ acetyl ⁇ -2 perhydro ⁇ soindolol-4- (3aS, 4S, 6S, 7aR) can be prepared by operating as described in Example 21, from 0.35 g of cyanomethyl-6 (2-methoxy phenyl) -4 perhydroisoindolol-4- (3aS, 4S, 6S, 7aR), 25 cm 3 of dichloromethane, 0 , 22 cm 3 of diisopropylethylamine, 0.32 g of ⁇ [(pyrrolidinyl-1) -3 propoxy] -2 phenyl ⁇ acetic acid, 0.01 g of hydroxybenzotriazole hydrate, and 0.26 g of hydrochloride of (dimethylamino-3 propyl) -1 ethyl-3 carbodumide.
- the oily residue obtained is chromatographed on an alumina column (particle size 100 mesh, height 30 cm, diameter 4.5 cm), eluting under a pressure of 0.7 bar of nitrogen with a mixture of cyclohexane and acetate ethyl (75/25 by volume) and collecting 100 cm 3 fractions. Fractions 1 to 6 are concentrated to dryness under reduced pressure (2.7 kPa). 2.9 g of ⁇ [(pyrrolidinyl-1) -3 propoxy] -2 phenyl ⁇ acetic acid are obtained in the form of a thick oil.
- Benzyl ⁇ [(pyrrolidinyl-1) -3 propoxy] -2 phenyl ⁇ acetate can be prepared as follows: To a solution 5.3 g of benzyl [(bromo-3 propoxy) -2 phenyl] acetate in 100 cm 3 of acetonitrile, 2.06 g of potassium carbonate, 0.5 g of sodium iodide and 1.25 cm 3 of pyrrolidine are added. After 3 hours of heating to 90 ° C., the mixture is cooled to room temperature, added with 50 cm 3 of water and then diluted with 50 cm 3 of dichloromethane.
- Benzyl [(bromo-3 propoxy) -2 phenyl] acetate can be prepared according to the following procedure:
- the oil obtained is chromatographed on a column of silica gel (particle size 0.06 - 0.200 mm, height 30 cm, diameter 5 cm), eluting with a mixture of cyclohexane and ethyl acetate (95/5 in volumes) and collecting 100 cm 3 fractions. Fractions 18 to 28 are concentrated to dryness under reduced pressure (2.7 kPa). 2.0 g of benzyl [(bromo-3 propoxy) -2 phenyl] acetate are obtained in the form of an oil.
- Benzyl [(hydroxy-2) phenyl] acetate can be prepared by operating according to the following procedure: A suspension of 22.6 g of 2-hydroxyphenyl acetic acid, 0.5 g of para.toluene acid sulfonic in 15.5 cm 3 of benzyl alcohol is brought to reflux for three hours. 2 g of 3S active carbon are added, the suspension is filtered on a supercel and the filtrate is evaporated to dryness under reduced pressure (2.7 kPa). Benzyl 30 * * (2-hydroxy) phenyl] acetate is obtained in the form of crystals. Mp K - 104 ° C.
- the present invention also relates to the pharmaceutical compositions constituted by a product of general formula (I) or a salt when they exist, optionally in combination with any other pharmaceutically compatible product, which may be inert or physiologically active.
- the compositions according to the invention can be used by parenteral, oral, sublingual, rectal, topical, transdermal, ocular, intranasal or aerosol for pulmonary purposes.
- the sterile compositions for parenteral administration which can in particular be used in the form of infusions are preferably aqueous or non-aqueous solutions, suspensions or emulsions.
- solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or d, can be used. other suitable organic solvents.
- These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating into the composition sterilizing agents, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in a sterile injectable medium.
- compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, senuptic glycerides or polyethylene glycols.
- compositions for oral administration tablets, pills, powders or granules can be used.
- the active product according to the invention (optionally combined with another pharma-ceutically compatible product) is mixed with one or more inert diluents or adjuvants, such as sucrose, lactose or starch.
- these compositions can also include substances other than diluents, for example a lubricant such as magnesium stearate.
- compositions for oral administration it is possible to use pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents such as water or paraffin oil.
- inert diluents such as water or paraffin oil.
- These compositions can also include substances other than diluents, for example wetting, sweetening or flavoring products.
- compositions for topical administration can be, for example, creams, ointments, or lotions.
- compositions for ocular administration may be instillations.
- compositions for intranasal administration can be pharmaceutically acceptable solutions or powders intended for drops or sprays.
- compositions can also be aerosols.
- the compositions can be stable sterile solutions or solid compositions dissolved at the time of use in sterile pyrogen-free water, serum or any other pharmaceutically acceptable vehicle.
- the active principle is finely divided and combined with a water-soluble solid diluent or vehicle with a particle size of 30 to 80 ⁇ m, for example dextran, mannitol or lactose.
- the products according to the invention can be particularly useful in the treatment of pain of traumatic, post-surgical, menstrual, cephalic origin, in cluster headache and in the treatment of migraines.
- the new isoindole derivatives are also useful in the treatment of inflammation in rheumatology, in the treatment of rheumatoid arthritis and in disorders due to dysregulation of the immune system, in the treatment of inflammations in dermatology such as psoriasis, herpes, urticaria, eczema, photodermatosis, burns and in inflammatory dental or ocular disorders and in the area of lachrymal secretions; they are also useful in the treatment of spasmodic, painful and inflammatory manifestations of the digestive tract (ulcerative colitis, irritable bowel syndrome, Crohn's disease), urinary tract (urinary hyperreflexia, cystitis) and respiratory tract (asthma , bronchial hypersecretion, chronic bronchitis, rhinitis
- the products according to the invention can also find application in the treatment of neurological diseases, Parkinson's disease, Alzheimer's disease, in the treatment of inflammatory and / or autoimmune and / or demyelinating diseases of the central and / or peripheral nervous system ( multiple sclerosis, Guillain-Barré syndrome, encephalopathies of viral origin ...), in neurological syndromes in relation to plasma extravasation (edema of the spinal cord, cerebral edema ”), in relation to the blood-brain barrier or in any spastic neurological syndrome (muscle relaxant treatments).
- the products according to the invention can also be useful in the treatment of anxiety, psychosis, schizophrenia, Huntington's disease or in the treatment of cardiovascular disorders such as hypotension.
- Another application can also be the treatment of gynecological disorders, the treatment of disorders linked to poor growth regulation (dwarfism, secondary hypothrophies to chronic childhood diseases, osteoporosis, development of grafts).
- the doses depend on the desired effect and on the duration of the treatment. For an adult, they are generally between 0.25 and 1500 mg per day in staggered doses.
- the doctor will determine the dosage he considers most appropriate based on age, weight and all other factors specific to the subject to be treated.
- Active product tablets having the following composition are prepared according to the usual technique: - [2-amino-2-phenyl acetyl- (S)] -2 cyanomethyl-6 (2-methoxy-phenyl) -4 perhydroisoindolol-4- ( 3aS, 4S, 6S, 7aR) 25 mg
- Active product tablets having the following composition are prepared according to the usual technique:
- Active product tablets having the following composition are prepared according to the usual technique: - azidomethyl-6 (2-methoxy-phenyl) -4 [(2-methoxy-phenyl) -2 propionyl- (S)] -2 perhydroisoindolol-4 - (3aS, 4S, 6R, 7aR) 25 mg
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8518340A JPH10509970A (ja) | 1994-11-30 | 1995-11-29 | サブスタンスpのアンタゴニストとしてのペルヒドロイソインドール誘導体 |
AU42654/96A AU4265496A (en) | 1994-11-30 | 1995-11-29 | Perhydroisoindole derivatives as antagonists of substance p |
US08/849,177 US5739351A (en) | 1994-11-30 | 1995-11-29 | Perhydroisoindole derivatives as substance P antagonists |
EP95941161A EP0794944A1 (fr) | 1994-11-30 | 1995-11-29 | Derives de perhydroisoindole comme antagonistes de la substance p |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/14345 | 1994-11-30 | ||
FR9414345A FR2727411B1 (fr) | 1994-11-30 | 1994-11-30 | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996016939A1 true WO1996016939A1 (fr) | 1996-06-06 |
Family
ID=9469302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1995/001577 WO1996016939A1 (fr) | 1994-11-30 | 1995-11-29 | Derives de perhydroisoindole comme antagonistes de la substance p |
Country Status (8)
Country | Link |
---|---|
US (1) | US5739351A (fr) |
EP (1) | EP0794944A1 (fr) |
JP (1) | JPH10509970A (fr) |
AU (1) | AU4265496A (fr) |
FR (1) | FR2727411B1 (fr) |
IL (1) | IL116154A0 (fr) |
WO (1) | WO1996016939A1 (fr) |
ZA (1) | ZA9510146B (fr) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
WO2007011820A2 (fr) | 2005-07-15 | 2007-01-25 | Amr Technology, Inc. | Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine |
WO2007041052A2 (fr) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
WO2007093827A1 (fr) | 2006-02-15 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac) |
WO2008120653A1 (fr) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Dérivé d'indoledione |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
WO2009111354A2 (fr) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Inhibiteurs de la tyrosine kinase |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
WO2010132442A1 (fr) | 2009-05-12 | 2010-11-18 | Albany Molecular Reserch, Inc. | 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation |
WO2010132487A1 (fr) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations |
WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
EP2336120A1 (fr) | 2007-01-10 | 2011-06-22 | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. | Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP) |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
WO2014085216A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions et procédés pour traiter le cancer |
WO2014100065A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituées en tant qu'inhibiteurs de hdm2 |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
US9085531B2 (en) | 2004-07-15 | 2015-07-21 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP3327125A1 (fr) | 2010-10-29 | 2018-05-30 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
US11096950B2 (en) | 2006-11-01 | 2021-08-24 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP4079856A1 (fr) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006007882A1 (de) * | 2006-02-21 | 2007-08-30 | Bayer Cropscience Ag | Cycloalkyl-phenylsubstituierte cyclische Ketoenole |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021155A1 (fr) * | 1992-04-10 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Derives de perhydroisoindole comme antagonistes de la substance p |
WO1995004040A1 (fr) * | 1993-07-30 | 1995-02-09 | Rhone-Poulenc Rorer S.A. | Derives de perhydroisoindole comme antagonistes de la substance p |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2676442B1 (fr) * | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
-
1994
- 1994-11-30 FR FR9414345A patent/FR2727411B1/fr not_active Expired - Fee Related
-
1995
- 1995-11-27 IL IL11615495A patent/IL116154A0/xx unknown
- 1995-11-29 US US08/849,177 patent/US5739351A/en not_active Expired - Fee Related
- 1995-11-29 JP JP8518340A patent/JPH10509970A/ja active Pending
- 1995-11-29 EP EP95941161A patent/EP0794944A1/fr not_active Ceased
- 1995-11-29 AU AU42654/96A patent/AU4265496A/en not_active Abandoned
- 1995-11-29 ZA ZA9510146A patent/ZA9510146B/xx unknown
- 1995-11-29 WO PCT/FR1995/001577 patent/WO1996016939A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021155A1 (fr) * | 1992-04-10 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Derives de perhydroisoindole comme antagonistes de la substance p |
WO1995004040A1 (fr) * | 1993-07-30 | 1995-02-09 | Rhone-Poulenc Rorer S.A. | Derives de perhydroisoindole comme antagonistes de la substance p |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499531B2 (en) | 2004-07-15 | 2016-11-22 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US9085531B2 (en) | 2004-07-15 | 2015-07-21 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
WO2007011820A2 (fr) | 2005-07-15 | 2007-01-25 | Amr Technology, Inc. | Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine |
US9403776B2 (en) | 2005-07-15 | 2016-08-02 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2007041052A2 (fr) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
WO2007093827A1 (fr) | 2006-02-15 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac) |
EP2946778A1 (fr) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
US11096950B2 (en) | 2006-11-01 | 2021-08-24 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2336120A1 (fr) | 2007-01-10 | 2011-06-22 | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. | Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP) |
EP2805945A1 (fr) | 2007-01-10 | 2014-11-26 | MSD Italia S.r.l. | Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase |
WO2008120653A1 (fr) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Dérivé d'indoledione |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
EP3103791A1 (fr) | 2007-06-27 | 2016-12-14 | Merck Sharp & Dohme Corp. | Dérivés de4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase |
WO2009111354A2 (fr) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Inhibiteurs de la tyrosine kinase |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US9498476B2 (en) | 2008-06-04 | 2016-11-22 | Albany Molecular Research, Inc. | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
WO2010132487A1 (fr) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations |
US9604960B2 (en) | 2009-05-12 | 2017-03-28 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
WO2010132442A1 (fr) | 2009-05-12 | 2010-11-18 | Albany Molecular Reserch, Inc. | 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation |
US9173879B2 (en) | 2009-05-12 | 2015-11-03 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
EP3330377A1 (fr) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
EP4079856A1 (fr) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
EP3327125A1 (fr) | 2010-10-29 | 2018-05-30 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
EP3919620A1 (fr) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
WO2014085216A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions et procédés pour traiter le cancer |
WO2014100065A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituées en tant qu'inhibiteurs de hdm2 |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
Also Published As
Publication number | Publication date |
---|---|
AU4265496A (en) | 1996-06-19 |
FR2727411B1 (fr) | 1997-01-03 |
IL116154A0 (en) | 1996-01-31 |
EP0794944A1 (fr) | 1997-09-17 |
US5739351A (en) | 1998-04-14 |
JPH10509970A (ja) | 1998-09-29 |
FR2727411A1 (fr) | 1996-05-31 |
ZA9510146B (en) | 1996-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996016939A1 (fr) | Derives de perhydroisoindole comme antagonistes de la substance p | |
EP0635003B1 (fr) | Derives de perhydroisoindole comme antagonistes de la substance p | |
EP0711280B1 (fr) | Derives de perhydroisoindole comme antagonistes de la substance p | |
EP0586490B1 (fr) | Derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1992020685A1 (fr) | Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1992020654A1 (fr) | Nouveaux derives de perhydroisoindole et leur preparation | |
HUT56064A (en) | Process for producing new isoindolow derivatives and pharmaceutical compositions containing them | |
EP0307303B1 (fr) | [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique | |
EP0635002B1 (fr) | Nouveaux derives de perhydroisoindole, et leur preparation | |
EP0625153B1 (fr) | Derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent | |
EP0693059B1 (fr) | Derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
CA1308715C (fr) | Derives de la phenothiazine, leur preparation et les compositions qui les contiennent | |
EP0271404B1 (fr) | Nouveaux dérivés du pyrrole, leur préparation et les compositions pharmaceutiques qui les contiennent | |
FR2709752A1 (fr) | Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
WO1995009628A1 (fr) | Application therapeutique de derives de perhydroisoindole comme antiemetique | |
EP0188150A1 (fr) | Procédé de préparation d'isomères optiques de thiazolo [3,2-a] pyrimidines, les nouveaux isomères ainsi obtenus, les compositions pharmaceutiques qui les contiennent et les intermédiaires pour mettre en oeuvre ce procédé | |
FR2710913A1 (fr) | Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995941161 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08849177 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995941161 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1995941161 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995941161 Country of ref document: EP |